Skip to main content

Table 3 Baseline characteristics of plantar warts according to treatment preference

From: The effect of patients’ preference on outcome in the EVerT cryotherapy versus salicylic acid for the treatment of plantar warts (verruca) trial

Characteristic

Treatment preference

P value

Salicylic acid

Cryotherapy

No preference

Type of verruca

    

Mosaic

5/28 (17.9)

16/86 (18.6)

24/104 (23.1)

0.73

Non-mosaic

23/28 (82.1)

70/86 (81.4)

80/104 (76.9)

 

Duration of verruca (months)

    

N

26

80

100

 

Mean(sd)

30.7 (27.5)

22.9 (19.6)

26.6 (27.3)

0.43

Median (interquartile range)

24.0 (12.0, 39.0)

18.0 (9.5, 29.0)

16.8 (8.5, 36.0)

 

Number of verrucae at baseline

    

N

28

86

101

 

Mean (sd)

4.3 (4.5)

3.8 (6.6)

3.3 (3.3)

0.50

Median (interquartile range)

3.0 (1.0, 5.5)

2.0 (1.0, 4.0)

2.0 (1.0, 4.0)

 

Previous treatment for current verruca

    

Yes

23/28 (82.1)

66/84 (78.6)

79/104 (76.0)

0.78

No

5/28 (17.9)

18/84 (21.4)

25/104 (24.0)

 

Type of previous treatment*

    

Self-treatment

21/23 (91.3)

53/66 (80.3)

73/80 (91.3)

0.15

Podiatrist/chiropodist

5/23 (21.7)

23/66 (34.9)

20/79 (25.3)

0.34

GP

10/23 (43.5)

30/66 (45.5)

27/80 (33.8)

0.32

Trial investigating verruca treatments

0/23 (0.0)

2/66 (3.0)

0/79 (0.0)

0.41

Other

3/23 (13.0)

6/66 (9.1)

5/79 (6.3)

0.50

  1. Values are n/N (%) unless otherwise stated.
  2. * Patients may have more than one previous verruca treatment.